Survival in MS
A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 8, 2011
- Accepted December 14, 2011
- First Published April 11, 2012.
Article Versions
- Previous version (April 11, 2012 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- D.S. Goodin, MD*,
- A.T. Reder, MD*,
- G.C. Ebers, MD,
- G. Cutter, PhD,
- M. Kremenchutzky, MD,
- J. Oger, MD,
- D. Langdon, PhD,
- M. Rametta, DO,
- K. Beckmann, MSc,
- T.M. DeSimone, PhD and
- V. Knappertz, MD
- D.S. Goodin, MD*,
Bayer Schering Pharma; Merck Serono
NONE
Occasional community lectures, symposia and/or academic talks sponsored by; Bayer Schering Pharma; Teva Neuroscience; Merck Serono, and; Novartis. In many cases, travel costs were reimbursed.
International MS Journal, Editorial Board, 2000-2009 Speakers’ Bureaus:; Bayer Schering Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Bayer Schering; Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I have served as an expert witness on various neurologic topics, 2008-2009
- A.T. Reder, MD*,
Abbott; ImmunoScience, Inc.; AstraZeneca; Merck Serono; Athena Diagnostics, Inc.; Sanofi- Aventis; Bayer Schering Pharma; Biogen Idec; BioMS Medical; Blue Cross Blue Shield; Boehringer Ingelheim; Caremark Rx; Centocor Ortho Biotech Inc.; Cephalon, Inc.; Connetics Corp.; CroMedica Global Inc.; Eli Lilly and Company; Elan Corporation; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Hoechst Marion Roussel Canada Research, Inc.; Roche; Immunex Corporation; Institute for Health Care Quality; Johnson & Johnson; Yale University; Barrow Neurological Institute; National Multiple Sclerosis Society & Paralyzed Veterans of America; Neurocrine Biosciences; Novartis; Parke-Davis; Pfizer Inc.; Pharmacia & Upjohn; Protein Design Labs, Inc.; Quantum Biotechnologies, Inc.; Quintiles, Inc.; EMD Serono, Inc., (39 Sention, Inc.; Smith Kline- Beecham; Specialized Therapeutics (a division of Berlipharm, Inc.); Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.
NONE
Abbott; ImmunoScience, Inc.; AstraZeneca; Merck Serono; Athena Diagnostics, Inc.; Sanofi- Aventis; Bayer Schering Pharma; Biogen Idec; BioMS Medical; Blue Cross Blue Shield; Boehringer Ingelheim; Caremark Rx; Centocor Ortho Biotech Inc.; Cephalon, Inc.; Connetics Corp.; CroMedica Global Inc.; Eli Lilly and Company; Elan Corporation; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Hoechst Marion Roussel Canada Research, Inc.; Roche; Immunex Corporation; Institute for Health Care Quality; Johnson & Johnson; Yale University; Barrow Neurological Institute; National Multiple Sclerosis Society & Paralyzed Veterans of America; Neurocrine Biosciences; Novartis; Parke-Davis; Pfizer Inc.; Pharmacia & Upjohn; Protein Design Labs, Inc.; Quantum Biotechnologies, Inc.; Quintiles, Inc.; EMD Serono, Inc., (39 Sention, Inc.; Smith Kline- Beecham; Specialized Therapeutics (a division of Berlipharm, Inc.); Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.
Medlink/Neurobase Editorial Board, Arbor Publishing Corporation, San Diego, CA, 1999-Present; Turkish Journal of Medical Sciences, Editorial Board, 2001- present; Türk Nöroloji Dergisi (Turkish Journal of Neurology), Editorial Board, 2004-present
NONE
NONE
NONE
Abbott; ImmunoScience, Inc.; AstraZeneca; Merck Serono; Athena Diagnostics, Inc.; Sanofi- Aventis; Bayer Schering Pharma; Biogen Idec; BioMS Medical; Blue Cross Blue Shield; Boehringer Ingelheim; Caremark Rx; Centocor Ortho Biotech Inc.; Cephalon, Inc.; Connetics Corp.; CroMedica Global Inc.; Eli Lilly and Company; Elan Corporation; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Hoechst Marion Roussel Canada Research, Inc.; Roche; Immunex Corporation; Institute for Health Care Quality; Johnson & Johnson; Yale University; Barrow Neurological Institute; National Multiple Sclerosis Society & Paralyzed Veterans of America; Neurocrine Biosciences; Novartis; Parke-Davis; Pfizer Inc.; Pharmacia & Upjohn; Protein Design Labs, Inc.; Quantum Biotechnologies, Inc.; Quintiles, Inc.; EMD Serono, Inc., (39 Sention, Inc.; Smith Kline- Beecham; Specialized Therapeutics (a division of Berlipharm, Inc.); Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.
NONE
NONE
NONE
Novartis; BioMS Medical; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Bayer Schering Pharma; EMD Serono, Inc.; Pfizer Inc.; Genentech, Inc.; Biogen Idec
NIH/NINDS RO1 NS 051591, Site PI; NIH 1 K24 RR021948, PI
NONE
the National MS Society; the Brain Research Foundation; the American Academy of Allergy & Immunology; Howard Hughes Foundation; Egypt Arab Republic Peace Fellowship; Turkish Ministry of Defense Fellowship Award; the State of Illinois
NONE
NONE
NONE
NONE
NONE
NONE
- G.C. Ebers, MD,
NONE
NONE
Bayer HealthCare Pharmaceuticals, funding for travel to meetings; Sanofi Aventis, speaker honorarium
International MS Journal, Editorial Board, present; Multiple Sclerosis, Editorial Board, present; BMC Medical Genetics, Section Editor, 2010-present
NONE
NONE
NONE
Biopartners; Bayer Healthcare Pharmaceuticals; Howrey LLP; Heron Health
NONE
NONE
NONE
Bayer Schering Pharma
NONE
NONE
MS Society of Canada Scientific Research Foundation, 2008-2011
NONE
NONE
NONE
NONE
NONE
I prepared 4 medico-legal reports, 2009-2011
- G. Cutter, PhD,
Participation of Data and Safety Monitoring Committees:; Sanofi-Aventis; Cleveland Clinic; Daichi- Sankyo; GlaxoSmithKline; Genmab Biopharmaceuticals; Eli Lilly; Medivation; Ono Pharmaceuticals; PTC Therapeutics; Teva; Vivus; Univ of Penn; NHLBI; NINDS; NMSS Consulting, Speaking fees & Advisory Boards:; Alexion; Bayhill; Bayer; Novartis; Consortium of MS Centers (grant); Klein-Buendel Incorporated; Peptimmune; Somnus Pharmaceuticals; Sandoz; Teva pharmaceuticals; UTSouthwestern; Visioneering Technologies, Inc
NONE
Consortium of MS Centers, speaker honoraria; Bayer, speaker honoraria
Multiple Sclerosis, Editorial Board, 2010-present
NONE
NONE
NONE
Consulting, Speaking fees & Advisory Boards:; Alexion; Bayhill; Bayer; Novartis; Consortium of MS Centers (grant); Klein-Buendel Incorporated; Peptimmune; Somnus Pharmaceuticals; Sandoz; Teva pharmaceuticals; UTSouthwestern; Visioneering Technologies, Inc
NONE
NINDS Grant with Multiple Sclerosis as the patient population
NONE
NONE
NIH/NINDS 5U01NS042685-06, PI, 2005-2015; NIH/NIDDK 1P30 DK079337, Co-I, 2008-2013; NIH/NINDS U01 NS45719-01A1, Co-I and Director of the Statistical and Data Management Center, 2003-2012; NIH/NIAID HHSN272201000023C, Co-I, 2010-2015; NIH/NIAIDS 5P30- A1027767, Co-I, 2009-2014; NMSS, Co-I, 2009-2013; NIH/NCRR 3UL1RR025777, Co-I, 2009-2011; NIH/NHLBI 5P50HL084923, Director of Coordinating Center, 2007-2012; NIH/NIA 2R01AG021927-06A1, Co-I, 2010-2015; NIH/NICHHD 1R01HD064729-01A1, Investigator/DCC PI, 2010- 2014; NIH/NIDDKD 2P30DK074038-06, Co-I, 2010-2015; CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS 000352886, Director of Data Center, 2009-open; NIH/NIDDK 1R01DK078826, 2009-2012; NIH/NINDS 5T32NS054584-05, 2011-2012; NIH - UNIVERSITY OF SOUTHERN CALIFORNIA H48487-01, 2011-2012; NIH/NHLBI 1U01HL102235-01A1, 2010–2013
NONE
Consortium of MS Centers
NONE
NONE
NONE
NONE
NONE
NONE
- M. Kremenchutzky, MD,
NONE
NONE
Funding for travel from; Biogen; Bayer; Teva
NONE
NONE
NONE
NONE
Biogen; Bayer; Teva; Sanofi; Novartis; Serono
NONE
NONE
NONE
Genzyme; Cell Gene; Biogen; Bayer; Teva; Sanofi; Novartis; Serono
CIHR
NONE
MS Society of Canada
NONE
NONE
NONE
NONE
NONE
NONE
- J. Oger, MD,
Advisory Board for; Biogen Idec; Bayer; Novartis; DSMB for an investigator initiated trial on MS
NONE
NONE
Multiple Sclerosis Journal, Editorial Board, 2000- 2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
research grant from Bayer on the matter of neutralizing antibodies to Interferons (NABs) received by UBC.; fees for NAB laboratory services from the Medical Services of British Columbia; fee for NAB laboratory services from Cinnagen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- D. Langdon, PhD,
Roche; Merck-Serono; Bayer; Novartis; Vertex
NONE
Presenting at scientific conferences:; Bayer; Novartis; Sanofi-Aventis; Serono Symposia
Multiple Sclerosis and Related Disorders,Psychology and Fatigue Section Editor, 2011-present; European Neurological Review, Editorial Board, 2010-present I do not receive any compensation for these journal positions
NONE
Verbal and Spatial Reasoning Test, Psychology Press, 1995- present
NONE
Bayer (Consultancy fees paid into my university charity account) Speakers’ Bureaus:; Serono; Bayer; Sanofi-Aventis; Novartis; Serono Symposia
NONE
NONE
NONE
Bayer, unrestricted educational grant for PhD studentship, 2005-8; Bayer, research contract to collect cognition data in 21Y LTF study, 2010-11
NONE
RHUL/SGUL, PhD studentship, 2006-9
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- M. Rametta, DO,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- K. Beckmann, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- T.M. DeSimone, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
I am a medical writer at PAREXEL, which was funded by Bayer HealthCare Pharmaceuticals to assist with the development of this manuscript.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- V. Knappertz, MD
NONE
NONE
NONE
NONE
NONE
NONE
Bayer Healthcare Pharmaceuticals, Global Medical Affairs, Multiple Sclerosis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (D.S.G.), University of California, San Francisco; Department of Neurology (A.T.R.), University of Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; Department of Biostatistics (G.C.), University of Alabama School of Public Health, Birmingham; London Health Sciences Center (M.K.), London, Canada; Neuroimmunology Laboratories and Multiple Sclerosis Clinic (J.O.), University of British Columbia, Vancouver, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, Surrey, UK; Bayer HealthCare Pharmaceuticals (M.R.), Wayne, NJ; Bayer HealthCare Pharmaceuticals (K.B.), Berlin, Germany; PAREXEL (T.M.D.), Hackensack, NJ; Bayer HealthCare Pharmaceuticals (V.K.), Montville, NJ; and Heinrich-Heine-Universität (V.K.), Düsseldorf, Germany.
- Correspondence & reprint requests to Dr. Goodin: douglas.goodin{at}ucsf.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSL. Kappos, A. Traboulsee, C. Constantinescu et al.Neurology, September 25, 2006 -
Articles
Long-term follow-up of clinical trials of multiple sclerosis therapiesMark S. Freedman et al.Neurology, December 27, 2010 -
Articles
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosisR. A. Rudick, D. E. Goodkin, L. D. Jacobs et al.Neurology, August 01, 1997 -
Article
Siponimod and Cognition in Secondary Progressive Multiple SclerosisEXPAND Secondary AnalysesRalph H.B. Benedict, Davorka Tomic, Bruce A. Cree et al.Neurology, December 16, 2020